Second, genetic testing does not capture epigenetic alterations such as BRCA1 promoter methylation, a mechanism of BRCA1 inactivation that is present in approximately 11% of ovarian cancers and 13% to 25% of breast cancers (9–12). This evidence concerns the gene BRCA1 and breast carcinoma.